Literature DB >> 23711663

Menopausal symptoms after the discontinuation of long-term hormone replacement therapy in women under 60: a 3-year follow-up.

Giuseppina Perrone1, Oriana Capri, Paola Galoppi, Francesca R Patacchioli, Elisa Bevilacqua, Maria G de Stefano, Roberto Brunelli.   

Abstract

BACKGROUND: Prescriptions for hormone replacement therapy (HRT) declined following the publication of the Women's Health Initiative study. The number of women who experience recurrence of menopausal symptoms after discontinuation of long-term HRT (LT-HRT), the length of time these symptoms last and the preferred alternative treatments remain unknown.
METHODS: This prospective 3-year follow-up study analyses the prevalence and intensity of menopausal symptoms that occur in young postmenopausal women who discontinued LT-HRT. Symptoms were evaluated using the Menopause Rating Scale.
RESULTS: Women (254) who discontinued LT-HRT (mean use: 6.9 ± 2.3 years) were recruited. Mean age at menopause was 48.1 ± 3.4 years. Mean age at discontinuation was 56.8 ± 3.7 years. 23% of the women were lost to follow-up. Of the remaining 196 women, 93% experienced a recurrence of menopausal symptoms within the first year, 25% resumed low-dose HRT, 62% used vaginal estrogens, 54% used phytoestrogens, and 2% used alternative therapies. A decrease in symptom prevalence and intensity was observed during the 3-year follow-up.
CONCLUSIONS: Symptoms re-appeared in a significant proportion of patients within the first year after discontinuation of LT-HRT. However, after 3 years, the majority of these women were asymptomatic. Patients who discontinue LT-HRT may require a more detailed follow-up immediately after the discontinuation of treatment.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23711663     DOI: 10.1159/000351104

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

1.  Notoginsenoside R1 prevents H9c2 cardiomyocytes apoptosis against hypoxia/reoxygenation via the ERs/PI3K/Akt pathway.

Authors:  Guang Li; Xiaoyan Xing; Yun Luo; Xuehong Deng; Shan Lu; Shimin Tang; Guibo Sun; Xiaobo Sun
Journal:  RSC Adv       Date:  2018-04-13       Impact factor: 4.036

2.  Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.

Authors:  Margery Gass; Joseph Larson; Barbara Cochrane; JoAnn E Manson; Dorothy Lane; Vanessa Barnabei; Judith Ockene; Marcia L Stefanick; Charles Mouton
Journal:  Menopause       Date:  2018-03       Impact factor: 2.953

3.  Starting and stopping menopausal hormone therapy and antidepressants for hot flushes: A case-based approach.

Authors:  Loukas Athanasiadis; Dimitrios G Goulis
Journal:  Case Rep Womens Health       Date:  2019-10-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.